Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Phase 1 Withdrawn
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
Phase 2 Withdrawn
Non-Viral TCR Gene Therapy
Phase 2 Withdrawn
Vaccine Response With NT-I7
Phase 1 Withdrawn
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Phase 1/2 Withdrawn
GRN1005 for Brain Metastases From Breast or Lung Cancer
Phase 2 Withdrawn
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
Phase 2 Withdrawn
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase 1/2 Withdrawn
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase 1 Withdrawn
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Phase 1 Withdrawn
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
Phase 2 Withdrawn
Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer
Phase 2 Withdrawn
Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer
Phase 2 Withdrawn